LOS ANGELES, Oct. 30, 2014 /PRNewswire/ -- ViaDerma, Inc.
(OTCQB: VDRM), a specialty pharmaceutical company devoted to
bringing new products to market, has recently released a
revolutionary new wound care drug called TetraStem. TetraStem is a
topical liquid tetracycline-based antibiotic that uses a
patent-pending innovative transdermal delivery system that can
convert oral medication active ingredients into topical drugs. The
drug is FDA registered as a first aid antibiotic to help prevent
skin infection in minor cuts, scrapes, and burns, but has also
shown to be effective in fighting methicillin-resistant
Staphyloccus aureus (MRSA) infections.
According to Mayo Clinic, Staph bacteria are normally found on
the skin or in the nose of about one-third of the population. The
bacteria are generally harmless unless they enter the body through
a cut or other wound, and even then they usually cause only minor
skin problems in healthy people. MRSA infection is caused by a
strain of staph bacteria that's become resistant to the antibiotics
commonly used to treat ordinary staph infections. This can allow
the infections to spread and sometimes become life-threatening.
According to the CDC MRSA kills about 11,000 people each year in
the United States.
ViaDerma's founder and CEO Dr. Christopher Otiko comments, "Initial case
studies involving TetraStem have showed remarkable success. The
most memorable was a woman in Florida who was on IV antibiotics for Systemic
MRSA. The patient's MRSA infection was drug resistant and the usual
medications were not working. However, after advising the patient
to apply TetraStem directly to her neck and wrist the patient was
symptom-free within two months."
ViaDerma is currently in negotiations to test TetraStem at
hospitals in Florida with plans to
expand the use of the drug across America. TetraStem is currently
being sold in various retail outlets. For more information about
TetraStem, please visit www.viadermalicensing.com.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher
Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty
pharmaceutical company committed to bringing new products to market
and licensing its innovative technology to current leaders in the
pharmaceutical industry in a wide variety of therapeutic areas.
ViaDerma's lead product, TetraStem, uses an innovative transdermal
delivery method to apply almost any active ingredient to a topical
drug. This patent-pending dual carrier transdermal technology may
be applied in products within the medical and cosmetic markets. For
more information, please visit www.viadermalicensing.com.
Forward Looking Statements
This press release
contains forward-looking statements that involve a number of risks
and uncertainties, including statements regarding the outlook of
the Company's business and results of operations. By nature, these
risks and uncertainties could cause actual results to differ
materially from those indicated. Generally speaking, any statements
using terms such as "will," "expect," "anticipate," or "may," or
which otherwise predict or address future results or events, are
likely to contain forward-looking statements. It is important to
note that actual results may differ materially from what is
indicated in any forward-looking statement. Readers should consider
any forward-looking statements in light of factors that could cause
actual results to vary. These factors are described in our filings
with the SEC, and readers should refer to those filings, including
Risk Factors described in those filings, in connection with any
forward-looking statements. The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE ViaDerma, Inc.
